<DOC>
	<DOCNO>NCT02366351</DOCNO>
	<brief_summary>The purpose study obtain information PK/PD , efficacy safety SHR3824 12 week Chinese patient Type 2 Diabetes . This do comparing effect SHR3824 placebo give oral dos .</brief_summary>
	<brief_title>The PK/PD , Efficacy , Safety Tolerability Study SHR3824 Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients must diagnosis type 2 diabetes mellitus ; Hemoglobin A1c level &gt; =7.5 % &lt; =10.5 % ; Body mass index ( BMI ) 25 45 kg/m2 ; Patient either previously treat antihyperglycemic medication treat antihyperglycemic last 10 week . Type I diabetes mellitus , diabetes mellitus result pancreatic disorder , secondary diabetes mellitus ( acromegaly , Cushing 's syndrome , etc . ) ; Past current history severe diabetic complication ( proliferative diabetic retinopathy , stage III later stage overt nephropathy , diabetic ketoacidosis , serious diabetic neuropathy ) ; Systolic blood pressure ≥160 mmHg diastolic blood pressure ≥100 mmHg start end day runin period ; History myocardial infarction , unstable angina , cerebrovascular disorder within 6 month start runin period ; Past current history malignant tumor ; Past current history drug hypersensitivity shock anaphylactoid symptom ; Pregnant woman , lactate mother , woman childbearing potential ; Any condition subject assess ineligible investigator ( sub investigator ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>